Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
CareDx (CDNA)
NASDAQ:CDNA
Holding CDNA?
Track your performance easily
CDNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.92 - $34.84
Previous Close$23.88
Volume1.18M
Average Volume (3M)898.36K
Market Cap
$1.28B
Enterprise Value$1.06B
Total Cash (Recent Filing)$240.85M
Total Debt (Recent Filing)$23.84M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Feb 26, 2025EPS Estimate
-$0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.70
Shares Outstanding53,633,871
10 Day Avg. Volume875,195
30 Day Avg. Volume898,358
Standard Deviation0.23
R-Squared0.16
Alpha0.00078
Financial Highlights & Ratios
Price to Book (P/B)4.69
Price to Sales (P/S)3.98
Price to Cash Flow (P/CF)24.90
P/FCF Ratio28.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.40
Enterprise Value/Gross Profit5.97
Enterprise Value/Ebitda-35.38
Forecast
1Y Price Target
$35.60Price Target Upside49.08% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
CareDx News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCDNA delivered $83M of revenue in Q3, matching its pre-announce and beating the Street by $3M.
Growth And ExpansionCDNA plans to hire ~50 more people to help provide even higher levels of customer support for AlloSure testing.
Regulatory And LegalCareDx announced that the Department of Justice concluded its investigation, found no wrongdoing, and is declining to take any further action.
Bears Say
Financial PerformanceCDNA shares were down 16% due to factors such as lower-than-expected Q3 revenue beat and volume growth, lack of full-year guidance reiteration, limited discussion on surveillance testing, and no Q&A during the Investor Day webcast.
Growth PotentialInvestors may question just how much growth CDNA can realistically capture from the 'portfolio halo effect' argument.
Regulatory ImpactUnder the draft LCD, surveillance testing using tests such as AlloSure Kidney would only be covered in a setting with an established biopsy protocol, potentially reducing annual revenue by as much as $70-$90 million.
---
Ownership Overview
8.02% Insiders
21.77% Mutual Funds
13.52% Other Institutional Investors
34.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CDNA FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was $6.92 and its highest was $34.84 in the past 12 months.
What is CareDx’s market cap?
Currently, no data Available
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Feb 26, 2025 which is in 110 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Nov 04, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.106.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is -$0.22.
How many shares outstanding does CareDx have?
CareDx has 53,633,870 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -0.131%.
Which hedge fund is a major shareholder of CareDx?
Among the largest hedge funds holding CareDx’s share is ARK Investment Management LLC. It holds CareDx’s shares valued at 89M.
---
CareDx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.60 (49.08% Upside)
$35.60 (49.08% Upside)
Blogger Sentiment
Neutral
CDNA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 253.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 10.9%
Last 30 Days ▲ 10.9%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
260.18%
12-Months-Change
Fundamentals
Return on Equity
-43.02%
Trailing 12-Months
Asset Growth
-4.83%
Trailing 12-Months
Company Description
CareDx
CareDx, Inc. operates as a transplant diagnostics company,which discovers, develops, and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure, and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.
---
CDNA Company Deck
---
CDNA Earnings Call
Q3 2024
0:00 / 0:00
---
CDNA Stock 12 Month Forecast
Average Price Target
$35.60
▲(49.08% Upside)
Technical Analysis
Best Analysts Covering CDNA
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
-9.61%
reiterated a buy rating 25 days ago
Copying Matthew Sykes's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -9.61% per trade.
---